Kangrui Yuan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kangrui Yuan has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Feipeng Jia
College of Mechanical and Electronic Engineering, Nanjing Forestry University, Nanjing 210037, China
2 shared publications - Jingcheng Wu
College of Mechanical and Electronic Engineering, Nanjing Forestry University, Nanjing 210037, China
2 shared publications - Zengxun Ni
College of Mechanical and Electronic Engineering, Nanjing Forestry University, Nanjing 210037, China
2 shared publications - Zhicheng Jia
College of Mechanical and Electronic Engineering, Nanjing Forestry University, Nanjing 210037, China
2 shared publications - Zineng Zhou
College of Food Science and Technology, Nanjing Agricultural University, Nanjing 210095, China
2 shared publications Chunyu Pan
Dongguan Key Laboratory of Precision Medicine Individualized Treatment Development, Department of Clinical Pharmacy, The Affiliated Dongguan Songshan Lake Central Hospital, Guangdong Medical University, Dongguan, China
1 shared publication
Latest Publications
- Open Access
- 23 May 2026
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 48 (6) , 550
Dauricine Mitigates Hypoxia Through Targeting ESR1, PIK3CA, and MTOR: A Network Pharmacology and Molecular Dynamics Simulation Investigation
Hypoxia is a prevalent pathophysiological condition. Prolonged exposure to hypobaric hypoxia can lead to maladaptation, increasing the risk of chronic hypoxic diseases such as high-altitude polycythemia (HAPC). Dauricine, an alkaloid derived from the root of Menispermum dauricum DC, has been demonstrated to possess anti-hypoxic properties; however, its underlying molecular mechanisms remain elusive. In this study, a potential multi-target anti-hypoxic mechanism of dauricine was proposed and computationally evaluated using an integrated approach combining network pharmacology, molecular docking, and molecular dynamics simulations. Common targets between dauricine and hypoxia-related genes were identified through network pharmacology screening. A protein–protein interaction (PPI) network was constructed to identify core targets, followed by Gene Ontology (GO) functional enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses. Molecular docking was subsequently employed to evaluate the binding affinities between dauricine and the candidate core targets, while molecular dynamics simulations were performed to assess the dynamic stability of the resulting complexes. Additionally, the drug-likeness and safety profiles of dauricine were assessed. The results suggest that dauricine may exert its anti-hypoxic effects by modulating candidate core targets, including ESR1, PIK3CA, and MTOR, and by acting on key signaling pathways such as PI3K-Akt, MAPK, and mTOR. This study provides a theoretical foundation for the further investigation of dauricine as a multi-target candidate for intervention in hypoxia and establishes a bioinformatics basis for subsequent experimental validation.
- 23 May 2026
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 48 (6) , 550
Open AccessDauricine Mitigates Hypoxia Through Targeting ESR1, PIK3CA, and MTOR: A Network Pharmacology and Molecular Dynamics Simulation Investigation
Hypoxia is a prevalent pathophysiological condition. Prolonged exposure to hypobaric hypoxia can lead to maladaptation, increasing the risk of chronic hypoxic diseases such as high-altitude polycythemia (HAPC). Dauricine, an alkaloid derived from the root of Menispermum dauricum DC, has been demonstrated to possess anti-hypoxic properties; however, its underlying molecular mechanisms remain elusive. In this study, a potential multi-target anti-hypoxic mechanism of dauricine was proposed and computationally evaluated using an integrated approach combining network pharmacology, molecular docking, and molecular dynamics simulations. Common targets between dauricine and hypoxia-related genes were identified through network pharmacology screening. A protein–protein interaction (PPI) network was constructed to identify core targets, followed by Gene Ontology (GO) functional enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses. Molecular docking was subsequently employed to evaluate the binding affinities between dauricine and the candidate core targets, while molecular dynamics simulations were performed to assess the dynamic stability of the resulting complexes. Additionally, the drug-likeness and safety profiles of dauricine were assessed. The results suggest that dauricine may exert its anti-hypoxic effects by modulating candidate core targets, including ESR1, PIK3CA, and MTOR, and by acting on key signaling pathways such as PI3K-Akt, MAPK, and mTOR. This study provides a theoretical foundation for the further investigation of dauricine as a multi-target candidate for intervention in hypoxia and establishes a bioinformatics basis for subsequent experimental validation.
- Open Access
- 5 May 2026
- Published by MDPI AG in Preprints.org
Dauricine Mitigates Hypoxia through Targeting ESR1, PIK3CA, and MTOR: A Network Pharmacology and Molecular Dynamics Simulation Investigation
Hypoxia is a prevalent pathophysiological condition. Prolonged exposure to hypobaric hypoxia can lead to maladaptation, increasing the risk of chronic hypoxic diseases such as high-altitude polycythemia (HAPC). Dauricine, an alkaloid derived from the root of Menispermum dauricum DC, has been demonstrated to possess anti-hypoxic properties; however, its underlying molecular mechanisms remain elusive. In this study, a multi-target molecular mechanism of dauricine in mitigating hypoxia was systematically investigated using an integrated approach combining network pharmacology, molecular docking, and molecular dynamics simulations. Common targets between dauricine and hypoxia-related genes were identified through network pharmacology screening. A protein-protein interaction (PPI) network was constructed to identify core targets, followed by Gene Ontology (GO) functional enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses. Molecular docking was subsequently employed to evaluate the binding affinities between dauricine and the core targets, while molecular dynamics simulations were performed to validate the stability of the resulting complexes. Additionally, the drug-likeness and safety profiles of dauricine were assessed. The results indicate that dauricine may exert its anti-hypoxic effects by modulating core targets, including ESR1, PIK3CA, and MTOR, and by acting on key signaling pathways such as PI3K-Akt, MAPK, and mTOR. This study provides a theoretical foundation for the development of dauricine as a multi-target candidate for intervention in hypoxia and establishes a bioinformatics basis for subsequent experimental validation.
- 5 May 2026
- Published by MDPI AG in Preprints.org
Open AccessDauricine Mitigates Hypoxia through Targeting ESR1, PIK3CA, and MTOR: A Network Pharmacology and Molecular Dynamics Simulation Investigation
Hypoxia is a prevalent pathophysiological condition. Prolonged exposure to hypobaric hypoxia can lead to maladaptation, increasing the risk of chronic hypoxic diseases such as high-altitude polycythemia (HAPC). Dauricine, an alkaloid derived from the root of Menispermum dauricum DC, has been demonstrated to possess anti-hypoxic properties; however, its underlying molecular mechanisms remain elusive. In this study, a multi-target molecular mechanism of dauricine in mitigating hypoxia was systematically investigated using an integrated approach combining network pharmacology, molecular docking, and molecular dynamics simulations. Common targets between dauricine and hypoxia-related genes were identified through network pharmacology screening. A protein-protein interaction (PPI) network was constructed to identify core targets, followed by Gene Ontology (GO) functional enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses. Molecular docking was subsequently employed to evaluate the binding affinities between dauricine and the core targets, while molecular dynamics simulations were performed to validate the stability of the resulting complexes. Additionally, the drug-likeness and safety profiles of dauricine were assessed. The results indicate that dauricine may exert its anti-hypoxic effects by modulating core targets, including ESR1, PIK3CA, and MTOR, and by acting on key signaling pathways such as PI3K-Akt, MAPK, and mTOR. This study provides a theoretical foundation for the development of dauricine as a multi-target candidate for intervention in hypoxia and establishes a bioinformatics basis for subsequent experimental validation.
- Open Access
- 25 February 2026
- Published by Springer Nature in Journal of Materials Science: Materials in Medicine
- Vol. 37 (1) , 42
A pH-responsive mesoporous Zn-MOF nanocarrier for efficient cisplatin delivery and inhibition of A549 cancer cells
Mesoporous metal-organic frameworks (MOFs) have the advantages of high specific surface area, tunable pore size, and favorable biocompatibility, making them promising candidates for drug delivery in cancer therapy. In this study, a series of mesoporous zinc-based MOF, constructed using cyclopentane dicarboxylic acid as the organic linker, was successfully synthesized via a surfactant-assisted solvothermal method. Surface characterization revealed that MOF-2 exhibited high surface area (1325 m2/g), pore volume (0.273 cm3/g), and average pore diameter (5.69 nm). UV-Vis analysis showed that MOF-2 demonstrated improved drug loading (18% w/w), encapsulation efficiency (86%), and cumulative release (96%), along with both pH-responsive degradation and drug release properties. Furthermore, cisplatin-loaded MOF-2 exhibited potent antitumor activity against A549 cells and effectively inhibited cell migration and invasion, while maintaining minimal cytotoxicity toward LO2 normal hepatic cells. These findings suggest MOF-2 as a promising nanocarrier for pH-responsive anticancer drug delivery. Graphical Abstract
- 25 February 2026
- Published by Springer Nature in Journal of Materials Science: Materials in Medicine
- Vol. 37 (1) , 42
Open AccessA pH-responsive mesoporous Zn-MOF nanocarrier for efficient cisplatin delivery and inhibition of A549 cancer cells
Mesoporous metal-organic frameworks (MOFs) have the advantages of high specific surface area, tunable pore size, and favorable biocompatibility, making them promising candidates for drug delivery in cancer therapy. In this study, a series of mesoporous zinc-based MOF, constructed using cyclopentane dicarboxylic acid as the organic linker, was successfully synthesized via a surfactant-assisted solvothermal method. Surface characterization revealed that MOF-2 exhibited high surface area (1325 m2/g), pore volume (0.273 cm3/g), and average pore diameter (5.69 nm). UV-Vis analysis showed that MOF-2 demonstrated improved drug loading (18% w/w), encapsulation efficiency (86%), and cumulative release (96%), along with both pH-responsive degradation and drug release properties. Furthermore, cisplatin-loaded MOF-2 exhibited potent antitumor activity against A549 cells and effectively inhibited cell migration and invasion, while maintaining minimal cytotoxicity toward LO2 normal hepatic cells. These findings suggest MOF-2 as a promising nanocarrier for pH-responsive anticancer drug delivery. Graphical Abstract